CY in combination with BU is a widely used conditioning regimen for haematopoietic SCT (HSCT). The aim of this study was to evaluate the pharmacokinetics (PK) of CY and its major metabolite 4-hydroxyCY (HCY) in patients with thalassemia undergoing HSCT. A total of 55 patients received BU (16 mg/kg) followed by CY (160 --200 mg/kg) both over 4 days before HSCT. A population PK model was developed to describe the disposition of CY and HCY and the inter-individual (IIV) and inter-occasion variability (IOV). The model was also used to determine the effects covariates including: demographics, Lucarelli classification and polymorphisms in enzymes involved in the metabolism or biotransformation of CY had on CY and HCY disposition. Overall, 17 --114% IIV and 12 --103% IOV in CY and HCY PK parameters were observed. Body weight and age were the main covariates, which explained the largest portion of the IIV. In addition, CYP2C9*2 explained a significant portion of the IIV in the clearance (Po0.002) and thus the area under the concentration curve (Po0.05) of CY. This covariate model may be used to design and plan targeted dose therapy in this group of pediatric patients, if clinical outcome association with CY PK are proved and target range established.
INTRODUCTION CY in combination with BU has been a commonly used conditioning regimen in HSCT for malignant and non-malignant diseases. 1 --3 Even though advances in transplantation practices including reducing the intensity of the conditioning regimen have improved the outcome of HSCT in recent years, 4, 5 doselimiting toxicities such as sinusoidal obstruction syndrome (SOS) and hemorrhagic cystitis 6, 7 remain as the major problems associated with BU-CY-based myeloablative-conditioning regimen. We and others have previously shown that BU pharmacokinetics (PK) influences toxicity and outcome associated with HSCT in patients with thalassemia major treated with BU/CY conditioning. 8 --10 The PK and pharmacodynamics of CY in pediatric patients receiving myeloablative doses of CY are limited and to the best of our knowledge, there is no report on CY PK in pediatric patients undergoing HSCT with myeloablative BU/CY-conditioning regimen. A recent study on the PK of CY and its metabolites in pediatric patients receiving high-dose myeloablative therapy 11 showed very little inter-patient variation in CY elimination, which is largely accounted for by body surface area, suggesting that high-dose chemotherapy resulted in minimal differences in CY PK as compared with more conventional dosage regimens. A population PK model was developed for the first time in children with neuroblastoma, 12 which showed substantial inter-patient variability in the PK of CY and its metabolites. Neither of these two studies described any pharmacodynamics associations. Several studies in adult patients have shown association between the incidence of SOS or hemorrhagic cystitis with increased exposure to metabolites of CY such as carboxyethylphosphoramide mustard and acrolein 13 --15 leading to increased non-relapse mortality and lower overall survival following HSCT. The extent of CY elimination has also been correlated with treatment efficacy and toxicity. 16 In addition, the PK and pharmacodynamics of CY has been shown to be conditioning regimen dependent the association between carboxyethylphospharamide mustard and SOS was seen only in patients receiving a CY/TBI regimen and not in those receiving a BU/CY regimen. 17 CY is a prodrug that has to be metabolized into 4-hydroxy CY (4-HCY) by various cytochrome P450 enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4 and CYP3A5) to exert its cytotoxic effect. 18 4-HCY exists in equilibrium with its tautomer aldophosphamide, which spontaneously degrades to the active alkylating species phosphoramide mustard and acrolein. 18 A major detoxification route of aldophosphamide is the oxidation to the inactive carboxyethylphospharamide mustard by aldehyde dehydrogenase enzymes (ALDH1A1 and ALDH3A1) 13 and a minor fraction is metabolized to dechloroethyl-CY by CYP3A4 and CYP3A5. In addition, GSTA1, P1, M1 and T1 are also involved in the detoxification of CY (12) . A wide degree of inter-patient variation in CY PK as well as clinical efficacy of treatment has been reported in adults and in children receiving conventional or high-dose CY. 19 --21 Although the PK of BU are well documented, 8, 22 technical difficulties in the accurate determination of CY metabolites have long hampered the assessment of the clinical pharmacology of this drug. 18, 19, 23 CY is known to have PK interactions with several drugs 18 such as fluconazole, ciprofloxacin, carboplatin, chloramphenicol, chlorpromazine, phenytoin, allopurinol and BU, most of which induce or inhibit the cytochrome P450 enzymes that are involved in CY metabolism. In addition, CY is known to exhibit autoinduction of its metabolism in patients receiving repeated administra-tion of CY for various disease conditions. 24, 25 In the context of conditioning for HSCT using chemotherapy alone, CY treatment is almost always preceded by BU, which has been shown to influence the PK of CY as well as aggravate the toxic effects including SOS, hemorrhagic cystitis and permanent alopecia. 26 --28 It is possible that wide inter-individual variation (IIV) in the PK of CY might be responsible for individual differences in toxicities or treatment outcome.
The population PK analysis might help develop dosing strategies for direct patient care as it targets the patient group that will eventually receive the drug of interest, quantitate PK variability at several levels and seeks to explain those sources of variability. 29 Limited data on PK as well as population PK of CY are available for various malignant and non-malignant conditions 12,30 --32 but there is no report in patients with thalassemia major, most of whom have varying degrees of chronic liver dysfunction due to iron overload. 33 In this study, we analyzed the PK of CY in patients with thalassemia major undergoing HSCT using a population PK-based approach, in order to explain the IIV in CY and HCY PK.
PATIENTS AND METHODS Patients
A total of 55 patients with beta thalassemia major who underwent allogeneic HSCT from HLA-identical parent or -sibling donors at the Department of Hematology, Christian Medical College, Vellore, India were included in the study. All the patients received oral BU 4 mg/kg p.o. in divided doses every 6 h daily for 4 days (total dose 16 mg/kg) on days À9 to À6 and CY 200 mg/kg actual body weight once daily i.v. over 1 h for 4 days on days À5 to À2 with ALG 30 mg/kg (Lymphoglobuline, Pasteur Meriuex, Paris, France) on days À4 to À2. BU plasma levels were neither targeted nor dose adjusted in this group of patients. All patients received 7.5 mg/kg p.o. of phenytoin in divided doses as prophylaxis against seizures, starting 1 day before and stopping 1 day after BU treatment. The time interval between the last dose of BU and the first dose of CY was not 424 h. They were also given appropriate hydration during the period of conditioning along with 2-mercaptoethanesulfonate at 140% of the dose of CY in seven equally divided doses during CY infusion days for prevention of hemorrhagic cystitis. 34 None of the patients received ursodiol for prophylaxis of SOS. All patients were risk stratified as per the Lucarelli classification, 33 and liver function as well as hepatitis B and C virus infections were assessed before transplant. Informed consent was obtained from the parents of all patients. The study was approved by the Institutional Review Board.
Pharmacogenetic analysis
Genomic DNA was extracted from peripheral blood from all patients collected before HSCT, using the standard phenol --chloroform method. These DNA samples were screened for common polymorphisms in the genes involved in the metabolism or biotransformation of CY namely GSTA1*B, GSTM1 and GSTT1 deletion, GSTP1 C341T, CYP2B6*6, CYP2C9*2, *3, CYP2C19*2, *3, CYP3A4*1B and ALDH1A1*2 and ALDH3A1*2 using PCR followed by RFLP analysis using methods described previously. 35 For ALDH3A1, a RFLP method was developed in-house and the variants were verified by sequencing.
Blood sampling for CY and HCY PK analysis A volume of 4 --5 mL of venous blood was collected in cold heparinized tubes before the start of first dose of CY and at 0.25, 0.5, 1, 3, 4, 7, 9 and 24 h on day 1 and day 4 of CY treatment. The blood samples were centrifuged immediately (at the patients' bed side) at 3000 r.p.m. for 3 min at 4 1C and plasma stored at --80 1C until CY analysis. As HCY is an unstable compound and requires immediate derivatization to a more stable derivative, a 500-mL volume of plasma was added to 1 ml of ice-cold acetonitrile, vortexed and centrifuged at 3000 r.p.m. for 3 min at 4 1C and the supernatant was separated as reported previously 20 and stored at À80 1C until analysis.
HPLC analysis of CY and HCY in plasma CY levels in plasma were analyzed using a previously reported method 36 on a reverse phase column (Phenomenex C18, , Torrance, CA, USA, 5 m, 250*4.6 mm), and detected with an online ultraviolet detector at the wavelength of 195 nm. A standard curve of CY with increasing concentration (10 --50 g/mL) was run each time along with each patient's sample. Briefly, the extraction was initiated by passing a mixture of (1 mL) patient plasma sample and (1 mL) Ifosfamide (internal standard at a concentration of 30 g/mL) to a C8-solid phase extraction column (Phenomenex), and eluted with 1 mL acetonitrile. The eluants were dried under a stream of nitrogen gas at 60 1C for 15 min and reconstituted with 300 mL of 100% methanol and injected on to the HPLC column. Mobile phase used was acetonitrile: potassium phosphate buffer (10 mM) in a ratio of 22.75:77.25, at a flow rate of 1.2 mL/min. CY levels were expressed as mg/mL. We established the limit of quantitation of CY to be 5 mg/mL. The assay was linear from 10 to 2000 mg/mL. The recovery from extraction was 95% (90 --98%). Inter and intra-day variation in all concentration range was o10%.
Levels of HCY were measured using previously published method 37 by HPLC with fluorescent detection using derivatization with danzylhydrazine. Briefly, supernatants were thawed and derivatized with danzylhydrazine in acidic condition, and the stable danzylhydrazone derivative of HCY was analyzed on a reverse phase column (Hypersil 3 , C18 (ODS), 100 Â 4.6 mm---Phenomenex), detected with online spectrofluorimetric detector (Shimadzu RF-10 AXL, Tokyo, Japan) at excitation wavelength of 350 nm and emission wavelength of 550 nm. A standard curve with increasing concentrations (50 --2500 ng/mL) of 4-hydroperoxyCY (Asta Medica, Frankfurt, Germany), which forms HCY in aqueous solution was run each time along with a patient sample. Mobile phase used was phosphate buffer (0.2 M) and acetonitrile in 2:1 ratio at a flow rate of 2 mL/min. HCY levels were expressed as mg/mL. The limit of quantitation of HCY was established to be 0.05 mg/mL. The assay was linear from 0.05 to 2.5 mg/mL. The recovery from extraction was 93 --100% and the intra and inter-day variation in all concentration range was o10%.
CY and HCY PK analysis
The population PK estimates were determined using non-linear mixed effects modeling analysis performed with Monolix (version 3.1, http://www.monolix.org). Specifically, the PK data were described using a compartmental model, which included two compartments for CY and one compartment for 4-HCY. The PK model is illustrated in Supplementary Figure 1 .
The PK parameters estimated included the elimination rate constants for each component (k 13 : CY elimination and k 30 : HCY elimination (1/h)), the volume for CY (V 1 (L or L/kg)), the apparent volume for HCY (V 3 /F 3 (L or L/kg) where F 3 is the unknown fraction converted to HCY), and the intercompartmental parameters (k 12 , k 21 : for CY (1/h)). In addition, the CY and HCY clearances (CL) were determined as follows: CY CL:
The distribution of the parameters was assumed log-normal. Therefore, IIV and inter-occasion (IOV) variability in parameters were modeled as exponential terms (Equation (1)):
where y i represents the estimated PK parameter for a given individual i, yis the population parameter estimate, Z y i describes the variation of individual i from the population estimate (that is, IIV), and Z y i1 þ Z y i2 represents the variability of the two occasions from the average value of individual I (that is, IOV). In all cases, Z was assumed normally distributed with mean zero and variance O. The intra-individual variability (residual error) was modeled using a mixed proportional and additive error model (Equation (2))).
where Cp ijk andĈp ijk represent the kth actual and predicted plasma concentration of the jth component (CY or HCY) in individual i, respectively. The error terms e rel and e abs are the components of the proportional (relative error) and additive errors (absolute error), respectively. Both are assumed to have a mean of zero and variance of s.
Estimates of C max (mg/mL) and area under the concentration curve from 0 to 24 h (AUC, mg*h/mL) for CY and HCY were determined using the individual post-hoc estimated concentration-time curves. As it has been shown that the PK of HCY is formation-rate limited, a better measure of exposure to this metabolite was suggested to be the ratio of AUC-HCY/ AUC-CY. 20 This is henceforth called AUC 4HCY/CY ratio in this article.
Covariate analysis
We studied the relation between the PK parameters and the patient's age, body weight, liver function tests, ferritin levels, genetic polymorphisms and Lucarelli class, first using a two-stage approach. 38 The individual conditional means were determined in the above described population PK analysis. Then linear mixed effects modeling (Matlab version 7.9, MathWorks, Natick, MA, USA) was used to investigate the effects of each covariate. Following this analysis, we also analyzed the covariates of the primary PK parameters that were significant (Po0.1) by the two-stage approach using the full population PK model via nonlinear mixed-effects modeling. In both cases, a covariate was considered significant in the univariate analysis if its addition to a hierarchical model reduced the À2 log likelihood at least 3.84 units (Po0.05; based on the w 2 test with one degree of freedom for the difference in the À2 log-likelihood).
RESULTS

Patient demographics
Overall, 55 patients were included in this study; their mean age was 7.27 ± 4.3 years (range 2 --14 years). There were 37 males and Population PK of CY and HCY CY and HCY PK data were available after the first and fourth doses of CY for 55 and 45 patients, respectively. Tables 1 and 2 show IIV and IOV of each CY and HCY PK parameters observed in this study. Overall, 17 --114% (coefficient of variation) IIV in CY and HCY PK parameters was noted. The visual predictive check of CY and HCY is shown in Figure 1 . In addition, the observed vs population predicted and individually predicted concentrations of CY and HCY were linear (Supplementary Figure 2) . After the i.v. infusion, the concentrations of CY and HCY declined bi-exponentially and in parallel, indicating that the kinetics of HCY is formation rate limited.
IIV in the PK of CY and 4-HCY Body weight normalization of dose was the main covariate, which explained the largest portion of the IIV and decreased the À2 loglikelihood the most (À37.9, Po10
À5
; Table 1 ). All the remaining covariates were compared with the weight normalized PK. There was a significant decrease in CY CL with respect to age (Po0.003), which explained 62% of its IIV relative to the weight normalized model. The population CY CL decreased 31% from 2 to 15 years (Supplementary Figure 3) . When we analyzed the kinetic parameters of CY and HCY with respect to Lucarelli's risk stratification, there was a trend to lower HCY apparent CL and higher HCY C max in class I or II compared with class III patients ( Table 2 ).
Pharmacogenetic analysis
The polymorphisms screened were all in Hardy --Weinberg equilibrium; the genotype frequencies of these polymorphisms are given in Supplementary Table 1 . The only significant relationship in the polymorphisms considered was between CY PK and CYP2C9*2. First, CY CL (L/h/kg) was 1.22 times higher in CYP2C9*2 HET vs WT (Po0.002; Table 2 ). This explained 40% of its IIV relative to the WT normalized model. This difference corresponded to CY AUC (mg*h/mL) being 1.34 times higher in CYP2C9*2 WT vs HET (median 1653; range: 900 --4303: vs median 1826; range: 1163 --9445; Po0.05; Figure 2 ). The remaining covariates we considered did not show a significant relation with any of the PK parameters.
IOV in the PK of CY and HCY Next, we investigated differences in CY PK between doses 1 and 4. The IOV (dose 1 vs 4) for CY and HCY CL (L/h/kg) was 44% and (Table 1) . We observed that the CL of HCY was 12% higher after the fourth dose compared with the first (Figure 3a ; P ¼ 0.05). In contrast, while there was large variability between occasions for CY CL, there was no significant association between the first and fourth course CY CL (Figure 3b ; P40.1). In addition, there was no correlation in the AUC of CY between the first and fourth doses (r ¼ 1EÀ3, P ¼ 1.0). But the AUC of HCY was correlated between the two doses (r ¼ 0.69, Po1EÀ6). Finally, we observed no significant correlation in the ratio of HCY AUC to CY AUC between the first and fourth doses (Figure 3c ; P40.1).
DISCUSSION
This study is the first report on the PK of CY and HCY in a homogeneous group of patients with beta thalassemia major undergoing HSCT conditioned with myeloablative BU/CY preparative regimen using a population PK-based approach. There was wide IIV (17 --114%) in CY and HCY kinetic parameters and using a population PK model, we tried to explain this variability. This model was also used to determine the effects covariates including: demographics, Lucarelli classification and polymorphisms in enzymes involved in the metabolism or biotransformation of CY had on CY and HCY dispositions. The main covariates that explained the variability in CY PK were body weight and age. Body weight as a factor influencing CY PK has been reported in patients with breast cancer receiving CY therapy. 39, 40 In addition, patients with CYP2C9*2 variant genotype showed significantly lower CY elimination and higher AUC. Recognizing the factors that influence CY and HCY PK in this pediatric population might help in designing individualization of therapy.
Using the full population PK model via nonlinear mixed-effects modeling, we observed significant decrease in CY CL with respect to age (Po0.003), which explained 62% of its IIV relative to the weight normalized model. This finding is similar to a previous report on CY POPPK where age explained the IIV 30 in children receiving both myeloablative and reduced doses of CY. Children tend to have more rapid CL of CY normalized to BSA relative to adults, although the mechanism remains unidentified. 41 --43 CY Cl (L/h/m 2 ) was significantly lower in our patient population compared with three studies in the pediatric population treated with myeloablative doses of CY (Table 3) . CY CL has been shown to be reduced in patients with hepatic dysfunction 44 and also in patients with Fanconi anemia 45 receiving lower than the myeloablative dose of CY. It is possible that the influence of age on CY CL in thalassemia and Fanconi anemia is masked by other factors including the disease itself.
Compared with previous reports from patients receiving BU/CYconditioning regimen, 17, 19, 20 there was significantly decreased formation of HCY and increased AUC of CY in this study resulting in lower AUC HCY/CY ratio (Table 4) . This difference in PK parameters could be age related because all the previous studies were from adult patients, whereas patients in this study are all under 15 years. There is also a possibility of disease-specific variation; all previous studies were performed in patients with hematological malignancies as compared with patients with thalassemia in this study. Factors such as disease status, genetic polymorphisms in the genes involved in transport and biotransformation of the drug, 35, 46 body weight, age and liver function have been shown to markedly influence the CY metabolism. 44, 47, 48 It has been reported that the biotransformation rate of CY was significantly reduced in patients with liver dysfunction but AUC of activated CY was relatively constant, indicating that impaired liver function does not influence efficacy and toxic effects of CY. 44 Other investigators have shown less toxicity in patients with hepatic failure, suggesting decreased exposure to activated CY. 47 PK of the metabolite in this study varied more than that of the parent drug similar to previous reports, probably due to differences in the expression of individual CYP450 enzymes involved in the metabolism of CY, especially CYP2B6, CYP2C9 or CYP3A4. 13, 16, 18 We observed 12 --103% IOV in CY and HCY PK parameters between first and fourth doses in this cohort of patients. The CL of HCY was significantly increased at the fourth dose compared with the first. However, the CY Cl and AUC, though showing a wide IOV, did not show any significant difference between doses. The IOV did not show a clear pattern of autoinduction of CY CL. Repeated administration of CY over a period of several consecutive days has been shown to induce its own metabolism. 21, 24, 25, 49 Several studies have shown detectable autoinduction of CY within 24 h after the initiation of CY infusion resulting in shorter CY T1/2, increased Cl/F and decreased AUC. 21, 24, 25, 49 The AUC of CY was increased and Cl decreased (Figure 3) after the fourth dose in as many as half of the patients included in this study. Phenytoin was used to prevent BU-induced seizures, and hence residual effects of phenytoin upon drug metabolism and transport would be present for day 1 but not for day 4. The reason for increased CY CL at fourth dose compared with first dose is not clear. It is known that the disposition of highdose CY by the CYP450 enzymes is a saturable process 50 while on the other hand, CY also shows autoinduction. 21, 24, 25, 49 Hence, the increase in AUC and decrease in Cl of CY that we observed on day 4 in some of our patients in this study could be due to nonpredictable variations in the balance between enzyme saturation and autoinduction.
We did not find any difference in CY PK between Lucarelli class II vs III thalassaemic patients in this study, excepting for decreased C max of HCY in class III patients. There is no report showing the association between parameters determining liver function and PK parameters of CY, unlike the case of BU PK, which has been shown to be influenced by ferritin levels. 51, 52 To better appreciate the role of liver dysfunction (as in thalassemia) on the PK and metabolism of CY, comparison of CY and HCY PK in age-matched patients with thalassemia vs other inherited or malignant disorders, without any liver dysfunction, undergoing HSCT receiving the same BU/CY regimen needs to be carried out.
Wide IIV in CY PK has been reported in patients receiving CY as part of the conditioning regimen, resulting in variable clinical response as well as toxicity. 21, 43, 53 Variability in CY PK has been explained by population PK models in various disease conditions 12, 31 but no such data exist in patients with thalassemia major. In this study, this variation was explained by body weight and CYP2C9*2 polymorphisms.
Previous reports on population PK of CY did not show these polymorphisms as factors explaining variation 35,54, however, association between ALDH1A1*2 polymorphisms and liver and bladder toxicity have been reported in patients treated with highdose CY. 55 Common functional polymorphism CYP2B6*6 in CYP2B6 gene, which is the major enzyme involved in the biotransformation of CY to HCY did not significantly explain the variation in CY and HCY PK in this cohort of patients, similar to the report of Ekhart et al. 35 However, it is important to note that patients in the Ekhart study received thiotepa, which is a known inhibitor of CYP2B6. CYP2C9*2 significantly increased CY AUC in this study, though previous reports have only shown association between CYP2B6*6 or CYP2C19*2 polymorphisms and CY PK. 46, 56 These results are a bit different than the results when we just considered CY alone 57 where ALDH1A1 and CYP3A4*1B variant genotypes significantly influenced CY PK. This difference could be because of the fact that the CY PK in these results are influenced by HCY. We have reported previously that CYP2C9*2 variant was significantly associated with increased TRM in a larger cohort of patients with thalassemia major undergoing HSCT. 58 Owing to the fairly large variability in PK among patients and small sample number, it was difficult to show significance. These may be worth looking into as larger data sets become available. In addition, genetic polymorphisms in the GST family of enzymes have been found to impact response and/or toxicity associated with CY-based therapies; especially the GSTP1 codon 105 (Ile4Val) polymorphism that reduce the detoxification ability of CY and/or its active metabolites appear to confer superior survival outcomes as well as increased risk of toxicity. 59 --61 However, none of the GST polymorphisms tested in this study explained the variation in CY or HCY PK in this cohort of patients. Owing to the small number of patients included in this study, clinical associations could not be done. In an ongoing study, we are continuing to analyze CY and metabolite PK in a larger cohort of patients, which should soon be available to make meaningful clinical outcome associations.
To conclude, we have developed a population PK model for CY in thalassaemic children. This model includes body weight and CYP2C9*2 genotype as covariates, which explain a significant portion of the variation in CY and HCY PK. This covariate model may be used to design and plan targeted dose therapy in this group of pediatric patients and to predict the risk of toxicity and outcome of HSCT if clinical association with CY and metabolite PK are proved. The results of this study should also be extended in other disease models in the Indian population. a CY PK data from pediatric patients included in the study were requested from investigators and obtained. 
